2010 A genetic variant in RASSF1A, a key regulator of HIPPO pathway, predicts survival in two independent cohorts of mCRC patients treated with cetuximab-based chemotherapy. (September 2015) - Sebio, A.; Stintzing, S.; Heinemann, V.; Zhang, W.; Sunakawa, Y.; Ichikawa, W.; Tsuji, A.; Takahashi, T.; Parekh, A.; Yang, D.; Cao, S.; Ning, Y.; et al.